Certain dideoxynucleosides have been shown to markedly inhibit the infectivity of human T-lymphotropic virus type m/lymphadenopathy-associated virus, the causative agent of acquired immunodeficiency syndrome (AIDS). Our present studies demonstrate that these drugs are broad spectrum antiretroviral agents capable of inhibiting the infectivity of evolutionarily divergent mammalian type C and animal lentiviruses. Under some conditions, virus infectivity could be inhibited by more than six orders of magnitude. However, the potency of these agents was shown to be greatly influenced by cell-specified determinants. Drug exposure during the initial 24 hr was almost as effective as prolonged treatment on the inhibition of a single cycle of virus infection and expression. Moreover, virus infection was shown directly to be inhibited at the level of proviral DNA synthesis. Thus the time period during which reverse transcription and provirus integration occur is the critical period required for drug action.
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Our findings have implications concerning strategies to be considered in attempts to utilize 2',3'-dideoxynucleosides in control and treatment of retrovirus-induced diseases ofanimals and humans.
In the past few years, efforts aimed at prevention and control of retroviral-induced diseases have gained increasing importance with accumulating evidence that such viruses are responsible for human as well as animal diseases. A potentially useful strategy has arisen from the application of a group of nucleoside analogues first synthesized over 20 years ago (1) (2) (3) (4) (5) . These dideoxynucleosides were shown to inhibit the retroviral reverse transcriptase (6) (7) (8) as well as cellular DNA polymerases f3 and y, while polymerase a was relatively resistant (8) (9) (10) (11) (12) . Initial studies aimed at demonstrating selective inhibition of viral replication by these drugs showed relatively modest effects (7, 8) . Recently, however, 3'-azido-3'-deoxythymidine (N3dThd; sometimes referred to as AZT) (13) and virtually all of the 2',3'-dideoxynucleosides (14) analyzed were found to powerfully and selectively inhibit replication of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV), § the retrovirus causative of acquired immunodeficiency syndrome (AIDS).
The AIDS virus has been shown to be closely related to animal lentiviruses (15) (16) (17) , whereas early investigations of these antiviral drugs focused upon distantly related type C viruses. Thus, it is not known whether the reported differences in their antiviral effects relate to host cell or viral specificities. Recently Mitsuya and his colleagues have shown that these nucleoside analogues act as chain terminators of the reverse transcription products of the incoming HTLV-III/LAV (18) , although this need not be the only mechanism for antiretroviral activity. Our present studies demonstrate a broad spectrum of antiretroviral activity by these agents, but show considerable cell variation in the potency of different agents. Under optimal conditions, the selective inhibition of even a single cycle of retroviral infection can be so profound as to suggest that these agents may have broad application in the control of diseases induced by retroviruses of animals and humans (19) (20) (21) (22) (23) (24) (25) (26) .
MATERIALS AND METHODS
Cells and Viruses. Animal lentiviruses, caprine arthritis encephalitis virus (CAEV) and equine infectious anemia virus (EIAV), were grown in Himalayan tahr (goat) ovary and equine dermis cells, respectively. The murine C type transforming retrovirus, Kirsten murine sarcoma virus (KiMuSV), with its associated amphotropic helper virus, amphotropic murine leukemia virus (amp-MuLV), was grown in NIH 3T3 cells. Other cells utilized include rat (NRK C113) and human (501T) fibroblast lines.
Nucleosides. The compounds 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, 2',3'-dideoxycytidine, and 2'-deoxycytidine were purchased from Calbiochem-Behring, whereas 2',3'-dideoxyguanosine and 2',3'-dideoxythymidine were purchased from Pharmacia. S. N. Lehrmann and D. Barry (Wellcome Research Laboratories, Research Triangle Park, NC) kindly provided N3dThd (BWA509U). Fig. 1 illustrates the structures of the dideoxynucleosides, including N3dThd (AZT), as well as normally utilized 2'-deoxyadenosine.
Infectivity Assays. For measurement of CAEV and EIAV infectivity, cells were grown in 24-well microtiter trays and pretreated for 4-5 hr with the indicated drug. Serial 10-fold dilutions of virus were added to wells (4 wells per dilution), the trays were incubated at 370C for 1 hr, and drug-containing medium was added to each well. At 2 weeks cultures were observed for cytopathic effect, and/or the culture fluids were tested for viral antigen by RIA. Drug effectiveness was determined by comparing the virus titer on drug-treated as opposed to untreated cells. Virus titer was defined as the reciprocal ofthe endpoint dilution at which =50% ofthe wells were virus positive.
Focus formation by Ki-MuSV was assayed as previously described (27) . Replication of type C helper virus was analyzed by testing tissue culture fluids for the mouse leukemia virus structural protein, p30, by competition RIA (28) .
RIAs. 
The key residues at the 3'-position on the deoxyribose moiety are circled. 2',3'-Dideoxythymidine (2',3'-ddThy) is identical to AZT except that a -H is substituted for the -N3 at the 3'-position of deoxyribose.
protein (p28, p24, and p30, respectively) present in clarified culture supernatants obtained from drug-treated and control cultures. Limiting antibody was incubated with serial dilutions of competing antigen followed by the addition of 10,000 cpm of purified iodinated viral protein (29) . The immune complexes were precipitated by the addition of excess antispecies immunoglobulin, collected by centrifugation, and the radioactivity of the pellets was determined as previously described (30) .
Southern Blot Analysis of the Effect of N3dThd on Proviral DNA Synthesis. Unintegrated Ki-MuSV DNA and ampMuLV DNA was obtained by Hirt extraction (31) of rat NRK C113 cells 24 and 72 hr after infection at a multiplicity of approximately 1 focus forming unit per cell. Half of the cultures were exposed to 100 AM N3dThd throughout the experiment. After electrophoresis, the DNA was transferred to nitrocellulose and hybridized (at 42°C for 16 hr) with a murine leukemia virus long terminal repeat (LTR) probe (32) in 50% formamide/0.02% (wt/vol) of bovine serum albumin, Ficoll, and polyvinyl pyrrolidone/100 ,g of sonicated salmon sperm DNA per ml/10% dextran sulfate/2.5 x SSC (1x SSC = 0.15 M sodium chloride/0.015 M sodium citrate, pH 7) . RESULTS
Spectrum of Inhibitory Activity of Dideoxynucleosides Against Animal Lentiviruses. HTLV-III/LAV replication has been shown to be potently inhibited by dideoxynucleosides such as 2',3'-dideoxycytidine and N3dThd, whereas a related analogue, 2',3'-dideoxythymidine, was markedly less effective (13, 14) . We sought to determine whether lentiviruses, to which the AIDS virus is related (15) (16) (17) , were inhibited by these agents. CAEV, like HTLV-III/LAV, is cytopathic in permissive cells, such as Himalayan tahr ovary. In contrast, EIAV induces no detectable cytopathic effect in equine dermis cells (33) .
When CAEV in tissue culture fluids was assayed at 2 weeks following infection in the presence or absence of drug, we observed an excellent correlation between CAEV detectable by RIA and cultures showing cytopathic effect. As shown in Fig. 2 , several of the 2',3'-dideoxynucleosides were very effective in inhibiting CAEV replication. In some cases, virus titers were decreased by more than five orders of magnitude. The minimum concentrations required in our assay system to achieve this degree of inhibition were 30 utM for 2',3'-dideoxyguanosine, 1.5 ,uM for 2',3'-dideoxycytidine, and 50 tkM for 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. In the same assay, 2',3'-dideoxythymidine and N3dThd were almost completely ineffective, as were the normal nucleosides, thymidine and 2'-deoxycytidine. At the drug concentrations tested, there was no obvious inhibition of cell growth by any of the compounds analyzed (Fig. 1) .
We observed striking differences in the effectiveness of several ofthese compounds when tested against EIAV titered in equine dermis cells. Fig. 3 compares the effect of different concentrations of 2',3'-dideoxyadenosine, 2',3'-dideoxycytidine, and N3dThd on the replication of CAEV in tahr cells and EIAV in equine cells. It is apparent that while CAEV was completely unaffected by up to 30 ,uM N3dThd, EIAV was inhibited by nearly five orders of magnitude by this concentration of the same drug. Thus, EIAV titered in equine dermis cells, as previously shown for HTLV-III/LAV in human lymphocytes (13) , appeared to be very sensitive to inhibition by N3dThd. Less marked differences in drug potency were observed with the other two drugs (Fig. 3, A and B ). 2',3'-Dideoxythymidine, as shown with HTLV-III/LAV (14) and CAEV (Fig. 2) was also ineffective in inhibiting the infectivity of EIAV (data not shown).
Antiretroviral Effectiveness of Dideoxynucleosides Is Cell Specified. The results presented above suggested either that distinct retroviruses exhibited very different sensitivities to specific nucleoside analogues or that the variations in sensitivity observed might result from differences in cellular properties. To investigate these possibilities, we compared the ability of different dideoxynucleosides to inhibit the infectivity of evolutionarily divergent retroviruses (15) in the same assay cells. As summarized in Table 1 , drug effectiveness correlated well with the assay cell utilized and was completely independent of the virus tested. In other studies, we tested the ability of N3dThd, 2',3'-dideoxycytidine and 2',3'-dideoxyadenosine to inhibit the replication of ampMuLV in cells of human, mouse, and rat origin. The degree of inhibition observed varied by up to five orders of magnitude among the three cell lines analyzed. For example, 2',3'-dideoxycytidine effectively inhibited amp-MuLV replication in human cells but had no effect on either NIH 3T3 or NRK C113 cells, while N3dThd was very potent in inhibiting amp-MuLV replication in the mouse and rat cells, and was moderately effective in the human fibroblast cells (data not shown). Thus, we conclude that cellular determinants predominate in determining dideoxynucleoside potency.
In earlier studies, it was shown that 2',3'-dideoxythymidine must be phosphorylated in order to inhibit in vitro activity ofthe reverse transcriptase ofretroviruses (7, 9) . Thus, the differences in potency might reflect differences in the levels of the necessary kinase(s) in cells of different tissues or species. Other cellular properties, such as nucleoside pool size and rates of transport into and out of the cell could also be important, because they would be expected to influence the concentration of the drug available to the kinase(s).
Dideoxynucleosides Inhibit Retrovirus Infection at an Early Step. In the above studies, retrovirus infectivity was quantitated under conditions that allowed multiple cycles of replication and virus spread. To more precisely measure the capacity of these agents to inhibit a single cycle of retrovirus integration and expression, we investigated their action on focus formation by Ki-MuSV. It is well established that only a single cycle ofvirus integration is required for a cell infected by this replication-defective transforming retrovirus to grow as a focus of transformed cells (27) .
Following treatment with either 2',3'-dideoxythymidine or N3dThd, mouse NIH 3T3 and rat NRK C113 cells were exposed when the drug exposure was limited to the first 24 hr (treatment 6). Pretreatment for 4 hr alone (treatment 2) led to only a modest effect, as did delay for 24 hr prior to drug addition (treatment 8), All of these findings established that 2',3'-dideoxynucleosides can effectively block the establishment of persistent retrovirus infection by cell exposure during the critical period during which reverse transcription and provirus integration would normally be expected. The known ability of the phosphorylated 2',3'-dideoxynucleosides to cause DNA chain termination in vitro led us to directly investigate the effect of the drugs on proviral DNA synthesis in vivo. We analyzed the effect of N3dThd on synthesis of unintegrated proviral Ki-MuSV and amp-MuLV (1) (2) (3) (4) . Some of these agents were shown to be effective in vitro inhibitors of Escherichia coli (35) and mammalian DNA polymerases (9) (10) (11) (12) , as well as reverse transcriptases (6) (7) (8) . Because of the modest effects seen with 2',3'-dideoxythymidine in inhibiting Rous sarcoma virus in chicken cells (6) and MuSV and MuLV in rodent cells (8) , efforts to further utilize these agents were not actively pursued. Recently, other 2',3'-dideoxynucleosides, but not 2',3'-dideoxythymidine, have been shown to be potent inhibitors of HTLV-III/LAV infectivity in tissue culture (13, 14) . Our present studies demonstrate that 2',3'-dideoxynucleosides are broad spectrum antiretroviral agents. They were able to reduce infectivity of animal lentiviruses and evolutionarily divergent mammalian type C retroviruses by several orders of magnitude under optimal conditions with minimal impairment in cellular growth properties.
We did observe striking differences in drug potency among different cell lines tested. Although the triphosphate derivatives of the 2',3'-dideoxynucleosides are known to be their active forms in in vitro reactions, triphosphates are not taken up by cells and, hence, the nonphosphorylated analogues have been utilized in these cell culture studies. Thus, variation in effectiveness ofthe 2',3'-dideoxynucleosides from cell line to cell line may reflect variations in endogenous levels of the relevant kinases and the corresponding phosphorylases. The active phosphorylated analogues are thought to act as chain terminators once they are incorporated into the nascent chain during DNA synthesis (36) (37) (38) . Indeed, Mitsuya et al. (18) have shown that phosphorylated dideoxynucleotides terminate DNA chains synthesized de novo by HTLV-III/LAV reverse transcriptase. There is some evidence that the level of a specific kinase is correlated with the effectiveness of a particular dideoxynucleoside. The conversion of 2',3'-dideoxynucleoside to phosphorylated derivatives is slow both in E. coli (36) and in most mammalian cells (12 We established that the first 24 hr of infection was the time period of drug exposure critical for its effectiveness. This corresponds to the time during which reverse transcription and proviral integration would be expected, consistent with the postulated action of these agents on the reverse transcription process. In a direct test of this, we showed that N3dThd-treatment of susceptible cells resulted in the profound inhibition of the synthesis of unintegrated proviral DNA (Fig. 6) . No inhibition of virus expression was observed if drug exposure was delayed 24 hr, implying little or no ability of these agents to inhibit expression of the integrated provirus. The magnitude of inhibition of a single cycle of virus infection was shown to be up to greater than six orders of magnitude, a profound effect considering the lack of detectable inhibition of cell proliferation under the same conditions.
The efficacy of these agents in cell culture is consistent with their potential applicability in the treatment or control of a variety of retroviral-induced diseases of animals and humans. However, our findings of major differences in susceptibility to these drugs among cell lines indicate a need for a systematic analysis of the response to dideoxynucleosides at the tissue and species level. This type of approach may reveal a combination of these agents that would most likely be effective in inhibiting retrovirus infection and spread. The tremendous potency of these agents in inhibiting a single round of virus infectivity further argues that a likely in vivo application would be in short term prophylaxis under conditions of high risk of retrovirus transmission, or in diseases in which target cell regeneration is possible and prevention of viral spread to uninfected target cells could still confer a benefit to the host.
